The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 07, 2018
Filed:
Jul. 12, 2013
Applicant:
Canadian Blood Services, Ottawa, CA;
Inventors:
Assignee:
CANADIAN BLOOD SERVICES, Ottawa, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/11 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 35/14 (2015.01); A61K 47/48 (2006.01); A61K 35/00 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 9/0019 (2013.01); A61K 35/14 (2013.01); A61K 39/001 (2013.01); A61K 39/0008 (2013.01); A61K 47/48776 (2013.01); C12N 5/0637 (2013.01); C12N 5/0638 (2013.01); C12N 15/113 (2013.01); A61K 35/00 (2013.01); A61K 47/48215 (2013.01); A61K 2035/122 (2013.01); A61K 2035/124 (2013.01); A61K 2039/515 (2013.01); A61K 2039/577 (2013.01); C12N 2310/141 (2013.01); C12N 2500/50 (2013.01); C12N 2501/00 (2013.01); C12N 2501/65 (2013.01); C12N 2502/1114 (2013.01);
Abstract
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.